Tetraphase Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2006-01-01
- Employees
- 67
- Market Cap
- -
- Website
- http://tphase.com
A Safety and PK Study of IV Eravacycline
- First Posted Date
- 2018-10-04
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03696550
- Locations
- 🇺🇸
Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States
🇺🇸University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
🇺🇸Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, California, United States
Phase 1, Safety and Bronchopulmonary PK Study in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03691584
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03450187
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
A Phase 1 Safety and PK Study of IV TP-271
- First Posted Date
- 2017-07-31
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03234738
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
- Conditions
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 1205
- Registration Number
- NCT03032510
A Phase 1 TP-271 Oral PK Single Ascending Dose Study
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03024034
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections
- Conditions
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT02784704
A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT02724085
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02135276
A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02135302
- Locations
- 🇺🇸
Davita Clinical Research, Lakewood, Colorado, United States
🇺🇸New Orleans Center for Clinical Research, Knoxville, Tennessee, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States